Canada Markets close in 1 hr 31 mins

Aprea Therapeutics, Inc. (APRE)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.9556-0.0237 (-2.42%)
As of 01:58PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.9793
Open0.9750
Bid0.9457 x 1200
Ask0.9556 x 1400
Day's Range0.9552 - 1.0099
52 Week Range0.6200 - 5.6700
Volume40,746
Avg. Volume926,943
Market Cap20.512M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

    BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET. The panel discussion will be hosted by R

  • GlobeNewswire

    Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on

  • GlobeNewswire

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

    BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended December 31, 2021 and provided a business update. Fourth Quarter Financial Results Cash and cash equivalents: As of December 31, 2021, the Company had $53.1 million of cash and cash equivalents